4884 Stock Overview Engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Kringle Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Kringle Pharma Historical stock prices Current Share Price JP¥810.00 52 Week High JP¥1,328.00 52 Week Low JP¥394.00 Beta 0.32 1 Month Change -5.81% 3 Month Change -7.22% 1 Year Change 14.89% 3 Year Change 20.90% 5 Year Change n/a Change since IPO -32.67%
Recent News & Updates
Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025 Nov 26
We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth Nov 25
Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024 Nov 13
Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024 Aug 29
Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024 Aug 22
Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation Jun 15 See more updates
Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025 Nov 26
We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth Nov 25
Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024 Nov 13
Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024 Aug 29
Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024 Aug 22
Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn Situation Jun 15
Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023) May 17
We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business Growth Mar 02
First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023) Feb 11
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024 Nov 29 Kringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024
Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022) Nov 17
New minor risk - Shareholder dilution Oct 24
Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023 Sep 02
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023 Aug 31
Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022) Aug 16
New minor risk - Shareholder dilution Jul 21
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023 May 30
First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022) May 19
First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022) Feb 12
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar Jan 17
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury Jan 13
Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021) Dec 28 Kringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023 Dec 01
Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar Nov 24
Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021) Nov 16
Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022 Nov 16
No independent directors Nov 16
Kringle Pharma, Inc. Submits Clinical Trial Application Oct 24
Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio University Sep 10
Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022 Sep 01
Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022 Aug 27
Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021) Aug 14
Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALS Aug 13
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022 Jun 01
Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021) May 17
Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury May 14
No independent directors Apr 27
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022 Feb 28
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 16
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Dec 19
Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022 Dec 17
Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of Als Dec 09
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021 Aug 21
Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021 Mar 05
Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021 Dec 30
Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million. Dec 29 Shareholder Returns 4884 JP Biotechs JP Market 7D -5.9% -1.7% -1.5% 1Y 14.9% 18.5% 13.7%
See full shareholder returns
Return vs Industry: 4884 underperformed the JP Biotechs industry which returned 18.5% over the past year.
Return vs Market: 4884 exceeded the JP Market which returned 13.7% over the past year.
Price Volatility Is 4884's price volatile compared to industry and market? 4884 volatility 4884 Average Weekly Movement 6.9% Biotechs Industry Average Movement 6.9% Market Average Movement 3.6% 10% most volatile stocks in JP Market 7.3% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 4884's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4884's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
Show more Kringle Pharma, Inc. Fundamentals Summary How do Kringle Pharma's earnings and revenue compare to its market cap? 4884 fundamental statistics Market cap JP¥5.52b Earnings (TTM ) -JP¥756.45m Revenue (TTM ) JP¥80.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4884 income statement (TTM ) Revenue JP¥80.04m Cost of Revenue JP¥0 Gross Profit JP¥80.04m Other Expenses JP¥836.49m Earnings -JP¥756.45m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -111.07 Gross Margin 100.00% Net Profit Margin -945.12% Debt/Equity Ratio 0%
How did 4884 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 12:31 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Kringle Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kyoichiro Shigemura Nomura Securities Co. Ltd.
Show 0 more analysts 
